Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Sarah L. Greig"'
Publikováno v:
Drugs & Therapy Perspectives. 33:555-565
Intravenous (IV) minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of many bacteria (e.g. Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp.). Minocycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31f382b9bd665d945ac1f25cd9d45108
https://doi.org/10.1007/s40267-017-0453-3
https://doi.org/10.1007/s40267-017-0453-3
Autor:
Sarah L. Greig
Publikováno v:
Drugs. 76:1403-1412
Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6618dc9f699990a2b8a5fc2690e28560
https://doi.org/10.1007/s40265-016-0634-8
https://doi.org/10.1007/s40265-016-0634-8
Publikováno v:
Drugs & Therapy Perspectives. 32:323-329
Pirfenidone (Esbriet®), a synthetic pyridine compound with antifibrotic, anti-inflammatory and antioxidant properties that inhibit the progression of tissue fibrosis, is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0e1c9cc7397108d1ff530d2d3d21cfe
https://doi.org/10.1007/s40267-016-0321-6
https://doi.org/10.1007/s40267-016-0321-6
Autor:
Sarah L. Greig
Publikováno v:
Drugs. 76:823-830
Obiltoxaximab (Anthim(®), ETI-204) is a monoclonal antibody that is being developed by Elusys Therapeutics and the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority for the prevention and treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0b0c8f63b40a07ca4192f4928ca55ab
https://doi.org/10.1007/s40265-016-0577-0
https://doi.org/10.1007/s40265-016-0577-0
Autor:
Sarah L. Greig
Publikováno v:
Drugs & Therapy Perspectives. 32:177-185
Carbidopa/levodopa enteral suspension [carbidopa/levodopa ES; Duopa™ (USA); Duodopa® (EU, where it is referred to as intestinal gel)] is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease (PD). Its de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::042362da2bcadb4491a8e962043b6aa6
https://doi.org/10.1007/s40267-016-0297-2
https://doi.org/10.1007/s40267-016-0297-2
Autor:
Sarah L. Greig
Publikováno v:
Drugs. 76:501-507
Oral dichlorphenamide (Keveyis™) is a carbonic anhydrase inhibitor that is approved in the USA for the treatment of primary hyperkalaemic and hypokalaemic periodic paralyses and related variants. The efficacy and safety of dichlorphenamide in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e81ba5cba806e9c34a04f542c1d7b5
https://doi.org/10.1007/s40265-016-0559-2
https://doi.org/10.1007/s40265-016-0559-2
Autor:
Sarah L. Greig
Publikováno v:
Drugs. 76:263-273
Osimertinib (Tagrisso(™), AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). Osimertin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e3fdd1336550a2bd06a5f84f0471b46
https://doi.org/10.1007/s40265-015-0533-4
https://doi.org/10.1007/s40265-015-0533-4
Autor:
Gillian M. Keating, Sarah L. Greig
Publikováno v:
Drugs & Therapy Perspectives. 31:417-424
Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave®, Mysimba™) is an effective adjunct to reduced-calorie diet and increased physical activity for chronic bodyweight management in adults who are eithe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efb4d6063b3f32ca21e53f32a1b20c55
https://doi.org/10.1007/s40267-015-0253-6
https://doi.org/10.1007/s40267-015-0253-6
Autor:
Sarah L. Greig
Publikováno v:
Drugs. 75:1687-1697
Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3996a407e4ae4edb67c003e256eb4551
https://doi.org/10.1007/s40265-015-0462-2
https://doi.org/10.1007/s40265-015-0462-2
Autor:
Sarah L. Greig, Lesley J. Scott
Publikováno v:
Drugs. 75:1523-1534
Insulin degludec/liraglutide (Xultophy(®)), a fixed-ratio combination of an ultra-long-acting insulin analogue and a glucagon-like protein-1 (GLP-1) receptor agonist, is available in the EU for the management of inadequately controlled type 2 diabet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a36a49d0dec700000f5bff17e806d358
https://doi.org/10.1007/s40265-015-0448-0
https://doi.org/10.1007/s40265-015-0448-0